Versatope announced that two new Board of Directors, Dr. Salim Yazji and Ms. Brenda McCabe joined the company to support the company’s strategy and management.

Versatope Therapeutics  received the first prize at the 11th Massachusetts Life Science Innovators (MALSI) conference 

Versatope delivers drugs and vaccines from genetically engineered probiotics. Article from the Lowell Sun newspaper. 

The 2018 200K M2D2 competition winners were announced on April 10th at Mintz Levin in Boston. Versatope took the second place prize. Congratulations to the team that worked hard to get us there.  

Advancing drug delivery: Convergence and Medical Devices/Drugs Symposium 

Versatope was selected as a resident company by Johnson & Johnson Innovation, JLABS at the M2D2 incubator in Lowell, Massachusetts 

Versatope selected as a finalist in the 200K M2D2 Challenge

Versatope Therapeutics  celebrated the launch of its new laboratory space at the Massachusetts Medical Device Development Center (M2D2) incubator at the University of Massachusetts Lowell.

Versatope won the the 1st Annual Massachusetts Jump Start Grant Challenge sponsored by  PharmaDirections, in cooperation with MassBio. 

This MassCONNECT® class includes entrepreneurs working to fight diabetes, discover drugs by screening in living animal models, revolutionize intravascular therapeutic embolization and deliver immunity with designer recombinant nanoparticles

128 high-impact companies to access global network of support and resources in Boston

A seasonal flu shot is a bit like a local weather forecast: Based on the conditions elsewhere and the direction of the prevailing wind, a meteorologist can give the public a pretty good idea of what to expect in the near future. Experts who track influenza’s intercontinental travels basically do the same thing.

For 30 years, conjugate vaccines have proven effective in reducing the incidence of disease caused by bacterial pathogens, including Haemophilus influenzae type b (Hib), a form of bacterial meningitis that kills thousands of infants annually in the underdeveloped world.

Mention E. coli and what pops into most people’s heads are bacteria, tainted food, a rush to the hospital – basically, fear. “E. coli gets a bad rap – and rightfully so,” said Matthew DeLisa, the William L. Lewis Professor of Engineering.